Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Mitochondrial Carrier Homolog 2 (MTCH2) Regulates the Differentiation of AML Cells By Controlling Pyruvate Entry into the Mitochondria, Nuclear Localization of Pyruvate Dehydrogenase Complex and H3 and H4 Histone Acetylation

Dilshad H. Khan, Michael Mullokandov, Yan Wu, Marcela Gronda, MSc, Rose Hurren, BSc, Xiaoming Wang, Neil MacLean, Danny V. Jeyaraju, PhD, G. Wei Xu, Rob C. Laister, PhD, Zachary Blatman, Troy Ketela, Mark D. Minden, MD PhD, Atan Gross, PhD, Aaron D. Schimmer, MDPhD

Blood (2017) 130 (Supplement 1): 299.

https://doi.org/10.1182/blood.V130.Suppl_1.299.299

Published: 2017

Journal Articles

Phase I Dose-Escalation Study of Cpi-613, in Combination with Bendamustine, in Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

Zanetta S. Lamar, MD, Scott Isom, MS, Rakhee Vaidya, MD, Anne W Beaven, MD, Zachariah A. McIver, DO

Blood (2016) 128 (22): 4163.

https://doi.org/10.1182/blood.V128.22.4163.4163

Published: 2016

Journal Articles

The Mitochondrial Carrier Homolog 2 (MTCH2) Regulates the Differentiation of AML Cells By Influencing the Localization of Pyruvate Dehydrogenase Complex and H3 and H4 Histone Acetylation

Dilshad H. Khan, PhD, Michael Mullokandov, Yan Wu, Marcela Gronda, Rose Hurren, Xiaoming Wang, Neil MacLean, Rob C. Laister, PhD, Atan Gross, Aaron D. Schimmer, MD PhD

Blood (2016) 128 (22): 1562.

https://doi.org/10.1182/blood.V128.22.1562.1562

Published: 2016

Journal Articles

Type B Lactic Acidosis in Advanced Diffuse Large B-Cell Lymphoma

Nancy El-Shamaa Kaddis, MD MPH

Blood (2016) 128 (22): 5420.

https://doi.org/10.1182/blood.V128.22.5420.5420

Published: 2016

Journal Articles

Platelet Lactate Production during Room Temperature Storage Promotes Bacterial Growth

Patrick Ketter, PhD MLS, MB (ASCP), Bernard Arulanandam, PhD, Andrew P Cap, MD PhD

Blood (2016) 128 (22): 2634.

https://doi.org/10.1182/blood.V128.22.2634.2634

Published: 2016

Journal Articles

The Mitochondrial Metabolism Inhibitor Cpi-613 Is Highly Active in Combination with High Dose Ara-C (HiDAC) and Mitoxantrone in a Phase I Study for Relapsed or Refractory Acute Myeloid Leukemia (AML)

Timothy S Pardee, MD PhD, Kristin Stadelman, MS, Scott Isom, MS, Leslie Renee Ellis, MD, Dmitriy Berenzon, MD, David D Hurd, MD, Robin Harrelson, BSN, Megan Manuel, MSN, Sarah Dralle, MSN, Susan Lyerly, PA, Bayard L. Powell, MD

Blood (2014) 124 (21): 3744.

https://doi.org/10.1182/blood.V124.21.3744.3744

Published: 2014

Journal Articles

A Phase I Study Of The Safety, Efficacy and Pharmacokinetics Of The First In Class Pyruvate Dehydrogenase Complex Inhibitor Cpi-613 In Patients With Advanced Hematologic Malignancies

Timothy Pardee, MD, PhD, King Lee, PhD, RAC, John Luddy, MS, Claudia Maturo, MS, Robert Rodriguez, BSc, MBA, Denise A Levitan, MD, David D Hurd, MD, Leslie Renee Ellis, MD, Scott Isom, MS, Robin Harrelson, BSN, Megan Manuel, MSN, Sarah Dralle, MSN, Susan Lyerly, PA, Bayard L. Powell, MD

Blood (2013) 122 (21): 486.

https://doi.org/10.1182/blood.V122.21.486.486

Published: 2013

Journal Articles

Altered Lipid and Mitochondrial Metabolism Are Viable Targets in Acute Leukemia,

Timothy Pardee, MD, PhD, Laura M DeFord-Watts, PhD, Erica Peronto, BS, Denise A Levitan, MD, David Duane Hurd, MD, Steven Kridel, PhD

Blood (2011) 118 (21): 3618.

https://doi.org/10.1182/blood.V118.21.3618.3618

Published: 2011

Journal Articles

Patients Who Respond to Donor Lymphocyte Infusion (DLI) Have an Antibody Response Against PDC-E2, the Immunodominant Autoantigens of Primary Biliary Cirrhosis (PBC), but with Different Specificity.

Roberto Bellucci, PhD, Meagan Gallagher, Sabine Oertelt, MD, Emmanuel Zorn, PhD, Edwin P. Alyea, MD, Robert J. Soiffer, MD, Catherine J. Wu, MD, Nikhil C. Munshi, MD, Eric Gershwin, MD, Jerome Ritz, MD

Blood (2005) 106 (11): 3105.

https://doi.org/10.1182/blood.V106.11.3105.3105

Published: 2005

Journal Articles

Inhibition of Hematopoietic Progenitor Cells by CD4 + T Cells Specific for an Endogenous Peroxisomal Protein, DRS-1: A Possible Mechanism for Bone Marrow Failure in Individuals Carrying HLA-DR15.

Xingmin Feng, Tatsuya Chuhjo, Xuzhang Lu, Hiroyuki Takamatsu, Chiharu Sugimori, Akiyoshi Takami, Shinji Nakao

Blood (2004) 104 (11): 1345.

https://doi.org/10.1182/blood.V104.11.1345.1345

Published: 2004

Journal Articles

PDC-E2, a Common Auto Antigen in Primary Biliary Cirrhosis (PBC) Is Also a Target of an Antibody Response in Patients Who Achieve Complete Remission after Donor Lymphocyte Infusion.

Roberto Bellucci, Ph.D, Meagan Gallagher, B.S., Hong-Nam Nguyen, Edwin P. Alyea, MD, Emmanuel Zorn, Ph.D, Kenneth C. Anderson, MD, Nikhil C. Munshi, MD, Jerome Ritz, MD

Blood (2004) 104 (11): 2121.

https://doi.org/10.1182/blood.V104.11.2121.2121

Published: 2004

NARROW

Mitochondrial Carrier Homolog 2 (MTCH2) Regulates the Differentiation of AML Cells By Controlling Pyruvate Entry into the Mitochondria, Nuclear Localization of Pyruvate Dehydrogenase Complex and H3 and H4 Histone Acetylation

Phase I Dose-Escalation Study of Cpi-613, in Combination with Bendamustine, in Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

The Mitochondrial Carrier Homolog 2 (MTCH2) Regulates the Differentiation of AML Cells By Influencing the Localization of Pyruvate Dehydrogenase Complex and H3 and H4 Histone Acetylation

Type B Lactic Acidosis in Advanced Diffuse Large B-Cell Lymphoma

Platelet Lactate Production during Room Temperature Storage Promotes Bacterial Growth

The Mitochondrial Metabolism Inhibitor Cpi-613 Is Highly Active in Combination with High Dose Ara-C (HiDAC) and Mitoxantrone in a Phase I Study for Relapsed or Refractory Acute Myeloid Leukemia (AML)

A Phase I Study Of The Safety, Efficacy and Pharmacokinetics Of The First In Class Pyruvate Dehydrogenase Complex Inhibitor Cpi-613 In Patients With Advanced Hematologic Malignancies

Altered Lipid and Mitochondrial Metabolism Are Viable Targets in Acute Leukemia,

Patients Who Respond to Donor Lymphocyte Infusion (DLI) Have an Antibody Response Against PDC-E2, the Immunodominant Autoantigens of Primary Biliary Cirrhosis (PBC), but with Different Specificity.

Inhibition of Hematopoietic Progenitor Cells by CD4 + T Cells Specific for an Endogenous Peroxisomal Protein, DRS-1: A Possible Mechanism for Bone Marrow Failure in Individuals Carrying HLA-DR15.

PDC-E2, a Common Auto Antigen in Primary Biliary Cirrhosis (PBC) Is Also a Target of an Antibody Response in Patients Who Achieve Complete Remission after Donor Lymphocyte Infusion.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only